COMP <GO>
EXPD vs TMO // EV/EBITDA & P/E VALUATION
Expeditors International of Washington Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: EXPD 8
— TMO 5
▲ EV/EBITDA & P/E VALUATION LEADER: EXPD
LAST: $198.85 (+0.23%) • MKT CAP: $25.85B
valuation
17.3x
LAST: $697.00 (-1.72%) • MKT CAP: $257.71B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXPD VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXPD | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 40.30% | 9.30% | +31.00 | EXPD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.3x | 30.4x | -13.10 | EXPD | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 2.40% | -0.43 | TMO | /fcf-yield <GO> |
| Operating Margin | 9.50% | 17.40% | -7.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.30% | 15.10% | -7.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 4.40% | 3.90% | +0.50 | EXPD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.80% | 0.24% | +0.56 | EXPD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.70 | 4.50 | +6.20 | EXPD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | EXPD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.8 | 56.8 | +3.00 | EXPD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.6x | 36.3x | -6.70 | EXPD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.85B | $257.71B | -$231.87B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXPD REV | TMO REV | EXPD GROSS % | TMO GROSS % | EXPD FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.07B | $44.56B | — | — | $508.4M | $6.29B |
| FY 2024 | $10.60B | $42.88B | — | — | $246.3M | $7.27B |
| FY 2023 | $9.30B | $42.86B | — | — | $634.7M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXPD // BETA 0.89
TMO // BETA 0.94